New vaccine aims to train immune system against hepatitis b
NCT ID NCT06989788
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works against the disease, only if it is safe and triggers an immune reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVX70371 (therapeutic hepatitis B vaccine)
What this could lead to
If successful, this could lead to a treatment that helps the immune system fight chronic hepatitis B, potentially reducing the need for lifelong medication.
What could go wrong
This is a very early Phase 1 trial with only 16 healthy participants, so it is primarily testing safety, not effectiveness. The vaccine may not produce a strong enough immune response or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium